Company intelligence / Profile preview

Artios Pharma

Cambridge, England, United Kingdomartios.com ↗

Ownership: Private
Development stage: Phase 2

Overview

ART0380 (ATR inhibitor) has shown promising clinical activity in the STELLA Phase 1/2a trial, with complete responses observed in metastatic pancreatic cancer and durable responses across multiple cancer indications in heavily pretreated patients. Initial Phase 2 data for ART0380 in combination with irinotecan in ATM deficient cancers is expected in H2 2024, and for the gemcitabine combination in platinum-resistant ovarian cancer in H1 2025.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

6 assets

art6043

5 more assets in the full pipeline.

Request access →

Partnerships

Cancer Research UKThe University of Texas MD Anderson Cancer CenterShangPharma InnovationSarah Cannon Research Institute (SCRI)

Beyond the preview

Go deeper on Artios Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Artios Pharma.

Explore the full profile